STUDresearch · Non-peptide
Garetosmab
Also known as
REGN2477 · anti-activin A antibody · Pasatru · garetosmab-grts · COURAGE triplet antibody
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Niche talk
Systemic
IV trial / labeled
Growth factors / muscle
Systemic anti-activin A antibody — COURAGE triplet and a separate FOP approval.
What people say
Garetosmab is an anti-activin A monoclonal antibody. COURAGE used it in a triplet with semaglutide and trevogrumab. A separate FOP approval (Pasatru) is not a physique indication.
Doses people talk about
Disease and obesity trial milligrams do not establish a DIY physique dose.
How it may feel
No credible physique self-use feel curve was found.
COURAGE triplet10 mg/kg IV
COURAGE triplet with semaglutide and higher-dose trevogrumab; monthly IV in that table.
FOP trial arms3 or 10 mg/kg IV
OPTIMA / approval reporting — disease program, not a recomp ladder.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- Felt durationNo consistent physique self-use timeline reported
Cycles people discuss
Public clocks are a 26-week obesity phase and a chronic FOP program, not a peptide camp.
Timing
COURAGE’s inspected triplet calendar is monthly IV, not a 19-day FLGR number.
Stacks
The public stack is the COURAGE triplet, not a kitchen peptide pile.
Watch for
Triplet discontinuation / tolerability is the COURAGE community one-liner. Read the table.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No inspected public DIY-vial half-life for garetosmab.
COURAGE uses a monthly IV triplet calendar; FOP dosing is a disease program. Neither is FLGR albumin lore.
Trial design is not a consumer PK table.
- Regeneron — COURAGE Phase 2 26-week results (triplet arm) (opens in a new tab)Triplet (semaglutide + trevogrumab + garetosmab 10 mg/kg) lean mass −2.0% at 26 weeks; larger fat-mass drop; tolerability/discontinuation discussed for the triplet.Obesity combination trial plus a separate FOP indication; not a gym peptide study.
Felt duration people report
No credible physique self-use feel curve was identified.
Talk is triplet DEXA and FOP headlines.
No verified n=1 antibody diaries.
- Regeneron — COURAGE Phase 2 26-week results (triplet arm) (opens in a new tab)Triplet (semaglutide + trevogrumab + garetosmab 10 mg/kg) lean mass −2.0% at 26 weeks; larger fat-mass drop; tolerability/discontinuation discussed for the triplet.Obesity combination trial plus a separate FOP indication; not a gym peptide study.
What people say
- The skeptic line vs FLGR: if skip-activin is the pitch, COURAGE’s extra activin block is the human counter-example people paste. Different molecules. forum
- No kitchen n=1 album with a verified antibody. forum
- COURAGE triplet 26-week DEXA: lean mass about −2.0% vs −6.5% semaglutide alone; fat-mass drop larger than antibody-without-activin arms. Obesity trial. trial
- FOP / Pasatru: FDA approval 2026 for reducing new HO lesions in adults with FOP — not a physique indication. trial
Doses people talk about
- No public DIY conversion. forum
- COURAGE triplet: garetosmab 10 mg/kg IV every 4 weeks with semaglutide and higher-dose trevogrumab. trial
- FOP label talk: 3 mg/kg and 10 mg/kg IV arms in OPTIMA reporting — disease program, not a recomp ladder. trial
- Framing: Trial / label milligrams. Not a peptide chart. trial
How it may feel
- Now: Triplet-arm screenshots and FOP-approval headlines. forum
- If a gray listing appears: no copied pump diary. forum
- Stop: no physique washout lore. forum
- COURAGE talk: more effect, more people stopping — that is the community one-liner. trial
Cycles people discuss
- Not an FLGR vendor block. forum
- COURAGE weight-loss phase reported at 26 weeks. trial
- FOP program is chronic disease treatment, not a 12-week blast. trial
Timing
- Do not paste FLGR numbers here. forum
- No inspected public DIY-vial half-life. trial
- COURAGE clock is monthly IV in the triplet, not a 19-day albumin story. trial
More on what it is
- Why people talk about it: COURAGE triplet screenshots (sema + trevogrumab + this) showed still-less lean-mass loss and more fat loss, with worse discontinuation talk. Skeptics use it against FLGR “skip-activin” marketing. forum
- Not DIY. Infusion/clinic product. forum
- What it is: Regeneron’s monoclonal antibody against activin A. Trial name garetosmab; FOP brand people now paste is Pasatru (garetosmab-grts). Not a peptide vial. trial
- How it works (plain): Activin A is the other big ActRII ligand in humans. Blocking it is a different job than blocking myostatin alone. trial
- FOP approval is a different disease. Heterotopic bone biology is not a gym recomp diary. trial
Stacks
- Compared with FLGR skip-activin claims, not co-injected in a kitchen. forum
- + Semaglutide + trevogrumab is the COURAGE triplet. trial
- FOP use is not a stack. trial
Storage notes
- Clinic product. forum
- Gray listings are identity risk. forum
Watch for
- Not a peptide SKU. forum
- Gray-vial identity. forum
- Triplet discontinuation / tolerability is the COURAGE community one-liner. Read the table. trial
- FOP is not a gym indication. trial
Evidence mix
More trial/lab tags than forum tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.